biote Corp. (BTMD) stock
Close on Nov 13, 2026Market cap $38.26MP/E –Yield –
Earnings
biote's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of biote's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Mar 10, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 4, 2026after the close | $43.30M | -9.8% | $0.01 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 5, 2026during market hours | $44.20M | -9.6% | -$0.23 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 6, 2026during market hours | $44.90M | -8.4% | $0.06 | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 11, 2026during market hours | $46.40M | -6.8% | $0.06 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 5, 2025during market hours | $48.00M | -6.6% | $0.22 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 6, 2025during market hours | $48.90M | -0.6% | $0.10 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 7, 2025during market hours | $49.00M | +4.7% | $0.37 | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 12, 2025during market hours | $49.80M | +9.0% | $0.10 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 12, 2024during market hours | $51.40M | +12.7% | $0.33 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 8, 2024during market hours | $49.20M | -0.2% | -$0.19 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 7, 2024during market hours | $46.80M | +4.5% | -$0.06 | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 12, 2024during market hours | $45.70M | +2.7% | $0.18 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 7, 2023during market hours | $45.60M | +8.6% | $0.24 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 10, 2023during market hours | $49.30M | +19.1% | -$0.25 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 9, 2023during market hours | $44.80M | +19.4% | -$0.39 | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 28, 2023during market hours | $44.50M | – | $0.18 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 8, 2022during market hours | $42.00M | – | -$1.74 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 10, 2022during market hours | $41.40M | – | – | Release |
| Q1 FY2022ended Mar 31, 2022 | Jun 9, 2022during market hours | $37.54M | – | $5.59 | Release |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
biote's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| Revenue | FY2026 | $175.00M | – | New | Nov 4, 2026 |
| Revenue | FY2026 | $175.00M | $190.00M | Lowered | Aug 5, 2026 |
| Adjusted EBITDAnon-GAAP | FY2026 | $25.00M | – | New | Nov 4, 2026 |
| Adjusted EBITDAnon-GAAP | FY2026 | $25.00M | $38.00M | Lowered | Aug 5, 2026 |
Guidance vs results
The last range biote gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| FY2025 | Revenue | $190.00M | $192.30MΣ4Q | Above range |
Guidance history
Every forecast biote put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Nov 4, 2026 | Adjusted EBITDA | FY2026 | $25.00M | New |
| Nov 4, 2026 | Revenue | FY2026 | $175.00M | New |
| Aug 5, 2026 | Adjusted EBITDA | FY2026 | $25.00M | Lowered |
| Aug 5, 2026 | Revenue | FY2026 | $175.00M | Lowered |
| May 6, 2026 | Adjusted EBITDA | FY2026 | $38.00M | Reaffirmed |
| May 6, 2026 | Revenue | FY2026 | $190.00M | Reaffirmed |
| Mar 11, 2026 | Adjusted EBITDA | FY2026 | $38.00M | New |
| Mar 11, 2026 | Revenue | FY2026 | $190.00M | New |
| Nov 5, 2025 | Adjusted EBITDA | FY2025 | $50.00M | New |
| Nov 5, 2025 | Revenue | FY2025 | $190.00M | New |
| Aug 6, 2025 | Adjusted EBITDA | FY2025 | $50.00M | Lowered |
| Aug 6, 2025 | Revenue | FY2025 | $190.00M | Lowered |
| May 7, 2025 | Adjusted EBITDA | FY2025 | $59.00M – $64.00M | Reaffirmed |
| May 7, 2025 | Dietary supplements revenue | FY2025 | +5% – +10% | Raised |
| May 7, 2025 | Procedure revenue | FY2025 | +2% – +4% | Lowered |
| May 7, 2025 | Revenue | FY2025 | $202.00M – $208.00M | Reaffirmed |
| Mar 12, 2025 | Adjusted EBITDA | Q1 FY2025 | -5% | New |
| Mar 12, 2025 | Adjusted EBITDA | FY2025 | $59.00M – $64.00M | New |
| Mar 12, 2025 | Procedure revenue | FY2025 | +2% – +4% | New |
| Mar 12, 2025 | Dietary supplements revenue | FY2025 | +5% – +10% | Raised |
| Mar 12, 2025 | Revenue | FY2025 | $202.00M – $208.00M | New |
| Nov 12, 2024 | Adjusted EBITDA | FY2024 | $58.00M – $61.00M | Lowered |
| Nov 12, 2024 | revenue | FY2024 | $197.00M – $201.00M | Lowered |
| Aug 8, 2024 | Adjusted EBITDA | FY2024 | $60.00M – $63.00M | Reaffirmed |
| Aug 8, 2024 | Revenue | FY2024 | $200.00M – $204.00M | Reaffirmed |
| May 7, 2024 | Adjusted EBITDA | FY2024 | $60.00M – $63.00M | Reaffirmed |
| May 7, 2024 | Revenue | FY2024 | $200.00M – $204.00M | Reaffirmed |
| Mar 12, 2024 | Adjusted EBITDA | FY2024 | $60.00M – $63.00M | Raised |
| Mar 12, 2024 | Revenue | FY2024 | $200.00M – $204.00M | New |
| Jan 17, 2024 | Adjusted EBITDA | FY2024 | $60.00M | New |
| Jan 17, 2024 | revenue | FY2024 | $200.00M | New |
| Nov 7, 2023 | Adjusted EBITDA | FY2023 | $56.00M – $60.00M | Reaffirmed |
| Nov 7, 2023 | Revenue | FY2023 | $190.00M – $200.00M | Reaffirmed |
| Aug 10, 2023 | Adjusted EBITDA | FY2023 | $56.00M – $60.00M | Reaffirmed |
| Aug 10, 2023 | Revenue | FY2023 | $190.00M – $200.00M | Reaffirmed |
| May 9, 2023 | Adjusted EBITDA | FY2023 | $56.00M – $60.00M | Reaffirmed |
| May 9, 2023 | Revenue | FY2023 | $190.00M – $200.00M | Reaffirmed |
| Mar 28, 2023 | Adjusted EBITDA | FY2023 | $56.00M – $60.00M | New |
| Mar 28, 2023 | Revenue | FY2023 | $190.00M – $200.00M | New |
| Nov 8, 2022 | Adjusted EBITDA | FY2022 | $47.00M – $51.00M | Reaffirmed |
| Nov 8, 2022 | revenue | FY2022 | $160.00M – $166.00M | New |
| Aug 9, 2022 | adjusted EBITDA | FY2022 | $47.00M – $51.00M | New |
| Aug 9, 2022 | revenue | FY2022 | $160.00M – $166.00M | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases biote filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- Results
- Update
- Results
- Results
- Results
- Update
- Results
- Update
- Results
- Update
- Results
- Results
See a number that looks wrong?